RedHill Biopharma (RDHL) Current Assets (2012 - 2025)

RedHill Biopharma (RDHL) has 14 years of Current Assets data on file, last reported at $6.5 million in Q4 2025.

• On a quarterly basis, Current Assets fell 45.19% year-over-year to $6.5 million in Q4 2025; TTM through Dec 2025 was $6.5 million, a 45.19% decrease from a year earlier, with the FY2025 full-year figure at $6.5 million, down 45.19% from the prior year.
• Current Assets for Q4 2025 stood at $6.5 million, down from $12.6 million in the prior quarter.
• Over the last five years, Current Assets for RDHL reached as high as $98.5 million in Q2 2021 and fell as low as $6.5 million in Q4 2025.
• Historically, Current Assets has averaged $45.5 million across 5 years, with a median of $21.6 million in 2023.
• Across the five-year window, Current Assets jumped 61.13% in 2021 and sank 81.21% in 2023, its largest moves.
• Year by year, Current Assets stood at $89.2 million in 2021, then slipped by 3.65% to $85.9 million in 2022, then sank by 81.21% to $16.1 million in 2023, then declined by 26.2% to $11.9 million in 2024, then plunged by 45.19% to $6.5 million in 2025.
• Per Business Quant data, the three most recent Current Assets figures were $6.5 million in Q4 2025, $12.6 million in Q2 2025, and $11.9 million in Q4 2024.